Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. Thus GCs, the sites of antibody affinity maturation triggered during immune responses, also provide an environment that facilitates B cell oncogenic transformation. miRNAs provide attractive and mechanistically different strategies to treat these malignancies based on their potential for simultaneous modulation of multiple targets. Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review recent advances that may help establish a basis for novel candidate miRNA-based therapies for B cell-NHL (B-NHL).

非霍奇金淋巴瘤（NHL）是一类不同的血液学癌症，其中许多起源于生发中心（GC）经历过的B细胞。因此，GCs，即免疫应答期间触发的抗体亲和力成熟的位点，也提供了促进B细胞致癌转化的环境。miRNA基于同时调节多个靶标的潜力，提供了有吸引力的且机制不同的策略来治疗这些恶性肿瘤。在这里，我们讨论了在B细胞瘤形成中基于miRNA的疗法的科学原理，并回顾了最近的进展，这些进展可能有助于为B细胞-NHL（B-NHL）的新型候选基于miRNA的疗法建立基础。